Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NKTR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNektar reports $1.02B cash after equity raise, initiates Phase 3 atopic dermatitis trials
Filed August 13, 2026 · Period ending August 13, 2026 · ~1 min read
Key Changes
-
high
Cash and investments reached $1.02B at June 30, 2026, up from $245.8M at year-end 2025, following April 2026 equity offering that raised $373.8M in gross proceeds. Cash runway extends into Q3 2028.
Exhibit 99.1 view on EDGAR → -
high
Initiated first two of three planned Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate-to-severe atopic dermatitis in July 2026. Phase 3 alopecia areata study planned for early 2027, with first BLA submission targeted for 2029.
Exhibit 99.1 view on EDGAR → -
medium
Q2 2026 net loss of $40.6M ($1.23 per share) versus $41.6M loss ($2.95 per share) in Q2 2025. Revenue declined to $10.1M from $11.2M year-over-year.
Exhibit 99.1 view on EDGAR → -
medium
R&D expenses increased to $39.1M in Q2 2026 from $29.9M in Q2 2025, driven by Phase 3 ZENITH AD program launch and rezpegaldesleukin manufacturing activities.
Exhibit 99.1 view on EDGAR → -
medium
Reported positive 52-week results from Phase 2b REZOLVE-AA study extension in April 2026, showing deepening responses to rezpegaldesleukin in severe-to-very-severe alopecia areata patients.
Exhibit 99.1 view on EDGAR →
Summary
Nektar Therapeutics reported Q2 2026 financial results showing a significantly strengthened balance sheet and advancement of its lead asset rezpegaldesleukin into late-stage development. The company's cash position jumped to $1.02 billion at quarter-end from $245.8 million at year-end 2025, primarily due to a $373.8 million equity offering completed in April 2026.
This capital raise extends Nektar's runway into Q3 2028, past the expected mid-2028 Phase 3 data readouts. The company initiated the first two of three planned Phase 3 ZENITH AD trials in July 2026, evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis. A third Phase 3 study in alopecia areata is planned for early 2027, with the first BLA submission targeted for 2029.
Operationally, Nektar reported a Q2 2026 net loss of $40.6 million on revenue of $10.1 million, with R&D expenses rising to $39.1 million as Phase 3 activities ramp up. The company's transition from Phase 2 to Phase 3 development represents a critical inflection point, with the capital raise providing the resources to execute through key clinical milestones over the next two years.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Nektar Therapeutics announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On August 13, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026.
Nektar disclosed its financial results for the quarter ended June 30, 2026 through a press release. The 8-K does not include the actual financial figures in the body text; those details are contained in the attached Exhibit 99.1 press release, which is not provided in this filing excerpt.
Event · Exhibit 99.1
Nektar reports Q2 2026 results: $1.02B cash after equity raise, Phase 3 atopic dermatitis trials initiated, net loss $40.6M.
Added in current filing · view on EDGAR →
Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025. ... Revenue in the second quarter of 2026 was $10.1 million as compared to $11.2 million in the second quarter of 2025. ... Net loss for the second quarter of 2026 was $40.6 million or $1.23 basic and diluted net loss per share as compared to net loss of $41.6 million or $2.95 basic and diluted loss per share in the second quarter of 2025.
Nektar reported Q2 2026 results showing cash and investments of $1.02 billion (up from $245.8 million at year-end 2025), revenue of $10.1 million (down from $11.2 million in Q2 2025), and a net loss of $40.6 million or $1.23 per share (compared to a $41.6 million loss or $2.95 per share in Q2 2025). The company states its cash runway extends into Q3 2028, past expected mid-2028 Phase 3 data readouts.
Added in current filing · view on EDGAR →
In April 2026, Nektar completed an underwritten public offering of its common stock resulting in $373.8 million of gross proceeds.
Nektar completed an underwritten public offering in April 2026 that raised $373.8 million in gross proceeds. This capital raise significantly strengthened the company's cash position and extended its runway to support Phase 3 development.
Added in current filing · view on EDGAR →
R&D expense in the second quarter of 2026 was $39.1 million as compared to $29.9 million for the second quarter of 2025. R&D expense in the first half of 2026 was $74.8 million as compared to $60.4 million for the first half of 2025. R&D expense increased primarily due to the commencement of activities to support the Phase 3 ZENITH AD program in atopic dermatitis as well as manufacturing activities associated with rezpegaldesleukin.
R&D expenses rose to $39.1 million in Q2 2026 from $29.9 million in Q2 2025, driven by the launch of Phase 3 ZENITH AD trials and manufacturing activities for rezpegaldesleukin. For the first half of 2026, R&D expenses totaled $74.8 million versus $60.4 million in the prior-year period.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 14, 2026 · How we verify